There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA – Research Report) and IGM Biosciences (IGMS – Research Report) with bullish sentiments.
Inventiva (IVA)
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Inventiva today and set a price target of $25.00. The company’s shares closed last Thursday at $3.62.
According to TipRanks.com, Samimy is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inventiva with a $20.33 average price target, a 466.7% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $14.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
IGM Biosciences (IGMS)
In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on IGM Biosciences, with a price target of $25.00. The company’s shares closed last Thursday at $12.13.
According to TipRanks.com, Willey is a 5-star analyst with an average return of
Currently, the analyst consensus on IGM Biosciences is a Moderate Buy with an average price target of $18.50, implying a 51.4% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $21.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IVA:
